A phase i dose-escalation study of antibody BI-505inRelapsed/refractorymultiplemyeloma

Clinical Cancer Research

Volumn 21, Issue 12, 2015, Pages 2730-2736

  Hansson, Markus ^a   Gimsing, Peter ^b   Badros, Ashraf ^c   Niskanen, Titti Martinsson ^d   Nahi, Hareth ^e   Offner, Fritz ^f   Salomo, Morten ^b   Sonesson, Elisabeth ^d   Mau Sorensen, Morten ^g   Stenberg, Yvonne ^d   Sundberg, Annika ^d   Teige, Ingrid ^d   Van Droogenbroeck, Jan ^h   Wichert, Stina ^a   Zangari, Maurizio ⁱ   Frendeus, Bjorn ^d   Korsgren, Magnus ^d   Poelman, Martine ^j   Tricot, Guido ^k  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d Clinical Development   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g Rigshospitalet   (Denmark)

^h General Hospital St Jan   (Belgium)

ⁱ UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^j Department of Genetic and Molecular Toxicology   (Belgium)

^k UNIVERSITY OF IOWA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; BI 505; C REACTIVE PROTEIN; CD19 ANTIGEN; CD38 ANTIGEN; HYDROCORTISONE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; PARACETAMOL; PREDNISOLONE; SYNDECAN 1; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; ADVANCED REFRACTORY MULTIPLE MYELOMA; ADVANCED RELAPSED MULTIPLE MYELOMA; AGED; ARTICLE; BODY TEMPERATURE DISORDER; CANCER GROWTH; CHILL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPERTENSION; HYPERVOLEMIA; HYPOTENSION; INFUSION RELATED REACTION; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPSIS; T WAVE INVERSION; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; DRUG MONITORING; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; TREATMENT OUTCOME;

EID: 84941955989     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3090     Document Type: Article

References (27)

1. Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-riskmultiple myeloma. Blood 2013;121: 884-92.
2. Boise LH, Kaufman JL, Bahlis NJ, Lonial S, Lee KP. The Tao of myeloma. Blood 2014;124:1873-9.
3. Gertz MA, Dingli D. How we manage autologous stem cell transplantation for patients with multiple myeloma. Blood 2014;124: 882-90.
4. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012;120:947-59.
5. Veitonmaki N, Hansson M, Zhan F, Sundberg A, Lofstedt T, Ljungars A, et al. A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell 2013;23:502-15.
6. Hsu JW, Dang NH. The role of monoclonal antibodies in the treatment of lymphomas. Expert Opin Biol Ther 2013;13:227-39.
7. Gasiorowski RE, Clark GJ, Bradstock K, Hart DN. Antibody therapy for acute myeloid leukaemia. Br J Haematol 2014;164:481-95.
8. Lianos GD, Vlachos K, Zoras O, Katsios C, Cho WC, Roukos DH. Potential of antibody-drug conjugates and novel therapeutics in breast cancer management. Onco Targets Ther 2014;7:491-500.
9. Bergsagel PL. Where we were, where we are, where we are going: progress in multiple myeloma. Am Soc Clin Oncol Educ Book 2014:199-203.
10. Donato F, Gay F, Bringhen S, Troia R, Palumbo A. Monoclonal antibodies currently in phase II and III trials for multiple myeloma. Expert Opin Biol Ther 2014;14:1127-44.
11. Laubach JP, Tai YT, Richardson PG, Anderson KC. Daratumumab granted breakthrough drug status. Expert Opin Investig Drugs 2014;23:445-52.
12. Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG III, Liu B. The development of potential antibody-based therapies for myeloma. Blood Rev 2014 Sep 28. [Epub ahead of print].
13. Kapoor P, Greipp PT, Morice WG, Rajkumar SV, Witzig TE, Greipp PR. Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol 2008;141:135-48.
14. Lutz RJ, Whiteman KR. Antibody-maytansinoid conjugates for the treatment of myeloma. MAbs 2009;1:548-51.
15. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011;186:1840-8.
16. Polson AG, Sliwkowski MX. Toward an effective targeted chemotherapy for multiple myeloma. Clin Cancer Res 2009;15:3906-7.
17. Ocio EM, Mitsiades CS, Orlowski RZ, Anderson KC. Future agents and treatment directions in multiple myeloma. Expert Rev Hematol 2014; 7:127-41.
18. Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol 2012;30:1960-5.
19. Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012;120: 552-9.
20. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 2013;19:3659-70.
21. San-Miguel J, Blade J, Shpilberg O, Grosicki S, Maloisel F, Min CK, et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 2014;123: 4136-42.
22. Hageman K, Patel KC, Mace K, Cooper MR. The role of denosumab for prevention of skeletal-related complications in multiple myeloma. Ann Pharmacother 2013;47:1069-74.
23. Teige I. Combination treatment with ICAM-1 antibody BI-505 and lenalidomide or bortezomib has potent antimyeloma activity in vivo. Clin Lymphoma Myeloma Leuk 2013;13:P-283.
24. Venkateshaiah SU, Bam R, Li X, Sharmin K, Wen L, Shelton RS, et al. Macrophages activation by ICAM1 antibody combined with lenalidomide has enhanced anti-myeloma activity in a supportive microenvironment in vivo and in vitro. Blood 2013;122.
25. Cheung IY, Hsu K, Cheung NK. Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2012;30:426-32.
26. Cheung NK, Cheung IY, Kramer K, Modak S, Kuk D, Pandit-Taskar N, et al. Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma. Int J Cancer 2014;135:2199-205.
27. Cheung NK, Cheung IY, Kushner BH, Ostrovnaya I, Chamberlain E, Kramer K, et al. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol 2012;30:3264-70.